Skip to main content

Free Content Estimating the global burden of multidrug-resistant tuberculosis among prevalent cases of tuberculosis

Download Article:
(PDF 200.0595703125 kb)
BACKGROUND: Estimates of the multidrug-resistant tuberculosis (MDR-TB) burden are based on incomplete, infrequently updated data among a limited pool of notified or incident pulmonary TB cases.

METHODS: Using World Health Organization data reported by 217 countries/territories in 2014, we calculated the MDR-TB burden among prevalent TB cases and compared these with estimates among incident and notified TB patients. We also compared treatment coverage across estimates.

RESULTS: Among prevalent TB patients worldwide in 2014, we estimate that 555 545 (95% credible bounds 499 340–617 391) MDR-TB cases occurred. This is 85% more than the 300 000 estimated among notified cases, and 16% more than the 480 000 among incident cases. Only 20% of MDR-TB cases among prevalent—compared to 37% of MDR-TB among notified—TB patients had access to MDR-TB treatment. Applying prior estimates, only 10% of MDR-TB cases will have successful outcomes.

CONCLUSION: Estimates based on likely-to-be-diagnosed cases of MDR-TB overlook a significant proportion of morbidity, mortality, and transmission that occur in undiagnosed, untreated, prevalent TB patients. Even though it may still likely underestimate the true disease burden, MDR-TB among patients with prevalent TB represents a closer approximation of disease burden than currently reported indicators. Progress toward elimination or control depends on policies guided by a more complete representation of the disease burden.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: drug-resistant TB; epidemiology; prevalence

Document Type: Research Article

Affiliations: 1: Department of Global Health, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands 2: Division of Global Health Equity, Brigham and Women's Hospital, Boston, Department of Biostatistics, Boston University School of Public Health, Boston, USA 3: Department of Global Health and Social Medicine, Harvard Medical School, Boston, Bouvé College of Health Sciences, Northeastern University, Boston, USA 4: Division of Global Health Equity, Brigham and Women's Hospital, Boston, USA; Department of Global Health and Social Medicine, Harvard Medical School, Boston, USA; Partners In Health, Boston, Massachusetts, USA

Publication date: 2017-01-01

More about this publication?
  • The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.

    Certain IJTLD articles are selected for translation into French, Spanish, Chinese or Russian. They are available on the Union website

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more